Another exciting day at #ACR21 and covering for @RheumNow Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use - DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg

Stopping/reducing hydroxychloroquine (HCQ) in SLE associated with increased flares, especially for those in low disease activity or in remission. Super helpful data to share with pts wanting to reduce/dc HCQ. #ACR21 Abst#0959 Plenary Session II @RheumNow https://t.co/i7jPDN2sgZ

How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and ⬆️wt based dose per day & CKD all risks. Abst#0989 #ACR21 #ACRBest @RheumNow https://t.co/XTfdQpVC7H

In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC

Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks #ACR21 @RheumNow https://t.co/Dl5WPo7mmj

NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG